Head-to-head · WeighScore
Aspire Health vs Gala Health
The verdict
Gala Health takes it — 82.9/100 to 59.2/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aspire Health | Gala Health |
|---|---|---|
| WeighScore | 59.2/100 | 82.9/100 |
| Grade | C | B− |
| Scorecard rank | #346 | #17 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | $179/mo (yearly subscription) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #346 · C
Strengths
- Both compounded and brand-name options (Wegovy + Zepbound) — rare among GLP-1 telehealth providers
- Lab orders with interpretation included in LoseIt membership — not billed separately
- Named clinical team: founded by Jenni Haan, MPAS, PA-C (18+ years experience) with four additional credentialed providers
- Slimpossible app + secure messaging for ongoing support between provider visits
- HSA/FSA accepted; Cherry third-party financing available for patients needing payment plans
Where it loses points
- Membership fee ($75/month) stacks on top of separately billed medication — total spend $205–$524/month depending on dose
- No LegitScript certification or independent third-party accreditation disclosed
- States served not publicly listed; availability depends on individual provider licensure
- All medication sales are final once shipped; consultation fee non-refundable once completed
- Compounding pharmacy partner not named on any public page
Graded #17 · B−
Strengths
- Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
- Prices are published openly rather than quiz-gated, with all doses included at the one rate
- All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet — injection only
- Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.